Download PDF
CC BY 4.0 · TH Open 2021; 05(03): e286-e294
DOI: 10.1055/s-0041-1730967
Original Article

Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis

Eman M. Mansory 
1   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
2   Department of Hematology, King Abdulaziz University, Jeddah, Saudi Arabia
,
Suthan Srigunapalan
3   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
,
Alejandro Lazo-Langner 
1   Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada
4   Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
› Author Affiliations Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
› Further Information
   Permissions and Reprints

Abstract

Introduction Venous thromboembolism (VTE) has been observed as a frequent complication in patients with severe novel coronavirus disease 2019 (COVID-19) infection requiring hospital admission.

Aim This study was aimed to evaluate the epidemiology of VTE in hospitalized intensive care unit (ICU) and non-ICU patients.

Materials and Methods PubMed was searched up to November 13, 2020, and updated in December 12, 2020. We included studies that evaluated the epidemiology of VTE, including pulmonary embolism (PE) and/or deep vein thrombosis (DVT), in patients with COVID-19.

Results A total of 91 studies reporting on 35,017 patients with COVID-19 was included. The overall frequency of VTE in all patients, ICU and non-ICU, was 12.8% (95% confidence interval [CI]: 11.103–14.605), 24.1% (95% CI: 20.070–28.280), and 7.7% (95% CI: 5.956–9.700), respectively. PE occurred in 8.5% (95% CI: 6.911–10.208), and proximal DVT occurred in 8.2% (95% CI: 6.675–9.874) of all hospitalized patients. The relative risk for VTE associated with ICU admission was 2.99 (95% CI: 2.301–3.887, p <0.001). DVT and PE estimated in studies that adopted some form of systematic screening were higher compared with studies with symptom-triggered screening. Analysis restricted to studies in the 5th quintile of sample size reported significantly lower VTE estimates.

Conclusion This study confirmed a high risk of VTE in hospitalized COVID-19 patients, especially those admitted to the ICU. Nevertheless, sensitivity analysis suggests that previously reported frequencies of VTE in COVID-19 might have been overestimated.

Keywords

venous thromboembolism - anticoagulation - COVID-19

Supplementary Material



Publication History

Received: 01 March 2021

Accepted: 06 April 2021

Article published online:
06 July 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Connors JM, Levy JM. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135 (23) 2033-2040
    CrossrefPubMedGoogle Scholar
  • 2 Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 2020; 29: 100639
    CrossrefPubMedGoogle Scholar
  • 3 Spyropoulos AC, Levy JH, Ageno W. et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1859-1865
    CrossrefPubMedGoogle Scholar
  • 4 Wells GA, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed April 27, 2021 at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp#:~:text=The%20Newcastle%2DOttawa%20Scale%20(NOS,%2C%20M%20Losos%2C%20P%20Tugwell%2C&text=The%20Newcastle%2DOttawa%20Scale%20(NOS)%20is%20an%20ongoing%20collaboration,%2C%20Australia%20and%20Ottawa%2C%20Canada
    PubMedGoogle Scholar
  • 5 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 6 Zerwes S, Hernandez Cancino F, Liebetrau D. et al. [Increased risk of deep vein thrombosis in intensive care unit patients with CoViD-19 infections?-Preliminary data] (in German). Chirurg 2020; 91 (07) 588-594
    CrossrefPubMedGoogle Scholar
  • 7 Al-Samkari HGS, Karp Leaf R, Wang W, Rosovsky R, Bauer K, Leaf D. STOP-COVID investigators. Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States. Res Pract Thromb Haemost 2020;4(suppl (Suppl 1
    PubMedGoogle Scholar
  • 8 Hanif A, Khan S, Mantri N. et al. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Ann Hematol 2020; 99 (10) 2323-2328
    CrossrefPubMedGoogle Scholar
  • 9 Berg S, Kim S-H, Patel S. et al. Real world outcomes of sars-Cov-2 thrombosis rates across three university health systems in the Chicago Metropolitan area. Blood 2020; 136 (supplement (Suppl. 01) 58-59
    CrossrefPubMedGoogle Scholar
  • 10 Piagnerelli M, Cauchie P, Vancutsem M. et al. Thromboprophylaxis in critically ill coronavirus disease 2019 patients. Crit Care Explor 2020; 2 (08) e0177
    CrossrefPubMedGoogle Scholar
  • 11 Stessel B, Vanvuchelen C, Bruckers L. et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study. Thromb Res 2020; 194: 209-215
    CrossrefPubMedGoogle Scholar
  • 12 Bompard F, Monnier H, Saab I. et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020; 56 (01) 17-20
    CrossrefPubMedGoogle Scholar
  • 13 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
    CrossrefPubMedGoogle Scholar
  • 14 Avruscio G, Camporese G, Campello E. et al; COVID-VTE Study Group. COVID-19 and venous thromboembolism in intensive care or medical ward. Clin Transl Sci 2020; 13 (06) 1108-1114
    CrossrefPubMedGoogle Scholar
  • 15 Hill JB, Garcia D, Crowther M. et al. Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. Blood Adv 2020; 4 (21) 5373-5377
    CrossrefPubMedGoogle Scholar
  • 16 Torres-Machorro A, Anguiano-Álvarez VM, Grimaldo-Gómez FA. et al. Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity. Thromb Res 2020; 196: 268-271
    CrossrefPubMedGoogle Scholar
  • 17 Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri FC. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to action. Thromb Res 2020; 196: 313-317
    CrossrefPubMedGoogle Scholar
  • 18 Choi JJ, Wehmeyer GT, Li HA. et al. D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. Thromb Res 2020; 196: 318-321
    CrossrefPubMedGoogle Scholar
  • 19 Lemos ACB, do Espírito Santo DA, Salvetti MC. et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359-366
    CrossrefPubMedGoogle Scholar
  • 20 Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L. et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020; 192: 23-26
    CrossrefPubMedGoogle Scholar
  • 21 Atallah B, Sadik ZG, Salem N. et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia 2021; 76 (03) 327-335
    CrossrefPubMedGoogle Scholar
  • 22 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
    CrossrefPubMedGoogle Scholar
  • 23 Boonyawat K, Chantrathammachart P, Numthavaj P. et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thromb J 2020; 18 (01) 34
    CrossrefPubMedGoogle Scholar
  • 24 Moores LK, Tritschler T, Brosnahan S. et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 2020; 158 (03) 1143-1163
    CrossrefPubMedGoogle Scholar
  • 25 Chen S, Zhang D, Zheng T, Yu Y, Jiang J. DVT incidence and risk factors in critically ill patients with COVID-19. J Thromb Thrombolysis 2021; 51 (01) 33-39
    CrossrefPubMedGoogle Scholar
  • 26 Nahum J, Morichau-Beauchant T, Daviaud F. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 2020; 3 (05) e2010478
    CrossrefPubMedGoogle Scholar
  • 27 Voicu S, Bonnin P, Stépanian A. et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J Am Coll Cardiol 2020; 76 (04) 480-482
    CrossrefPubMedGoogle Scholar
  • 28 Zhang L, Feng X, Zhang D. et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 2020; 142 (02) 114-128
    CrossrefPubMedGoogle Scholar
  • 29 Robert-Ebadi H, Righini M. Should we diagnose and treat distal deep vein thrombosis?. Hematology (Am Soc Hematol Educ Program) 2017; 2017 (01) 231-236
    CrossrefPubMedGoogle Scholar
  • 30 McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2 (07) e437-e445
    CrossrefPubMedGoogle Scholar
  • 31 Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127: 104362
    CrossrefPubMedGoogle Scholar
  • 32 Kaplan D, Casper TC, Elliott CG. et al. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest 2015; 148 (05) 1224-1230
    CrossrefPubMedGoogle Scholar
  • 33 Zhang C, Zhang Z, Mi J. et al. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine (Baltimore) 2019; 98 (23) e15833
    CrossrefPubMedGoogle Scholar
  • 34 Poissy J, Goutay J, Caplan M. et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142 (02) 184-186
    CrossrefPubMedGoogle Scholar
  • 35 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
    CrossrefPubMedGoogle Scholar
  • 36 Mei F, Fan J, Yuan J. et al. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol 2020; 40 (09) 2332-2337
    CrossrefPubMedGoogle Scholar
  • 37 Tan JY, Tan CW, Wong WH. et al. Thrombotic events in COVID-19 patients and Its comparison with other non-SARS-Cov-2 respiratory viruses. Blood 2020; 136 (suppl (Suppl. 01) 25-26
    CrossrefPubMedGoogle Scholar
  • 38 Freund Y, Drogrey M, Miró Ò. et al. Association between pulmonary embolism and COVID‐19 in ED patients Undergoing CTPA: the PEPCOV international retrospective study. Acad Emerg Med 2020; 27: 811-820
    CrossrefPubMedGoogle Scholar
  • 39 Salisbury R, Iotchkova V, Jaafar S. et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv 2020; 4 (24) 6230-6239
    CrossrefPubMedGoogle Scholar
  • 40 Patell R, Bogue T, Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020; 136 (11) 1342-1346
    CrossrefPubMedGoogle Scholar
  • 41 Roberts LN, Whyte MB, Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136 (11) 1347-1350
    CrossrefPubMedGoogle Scholar
  • 42 Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis 2020; 50 (02) 278-280
    CrossrefPubMedGoogle Scholar
  • 43 Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Heide RSV. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv 2020; DOI: 10.1101/2020.04.06.20050575.
    CrossrefPubMedGoogle Scholar
  • 44 Dubois-Silva Á, Barbagelata-López C, Mena Á, Piñeiro-Parga P, Llinares-García D, Freire-Castro S. Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019. Intern Emerg Med 2020; 15 (05) 865-870
    CrossrefPubMedGoogle Scholar
  • 45 Contou D, Pajot O, Cally R. et al. Pulmonary embolism or thrombosis in ARDS COVID-19 patients: a French monocenter retrospective study. PLoS One 2020; 15 (08) e0238413
    CrossrefPubMedGoogle Scholar
  • 46 Benito N, Filella D, Mateo J. et al. Pulmonary thrombosis or embolism in a large cohort of hospitalized patients with COVID-19. Front Med (Lausanne) 2020; 7: 557
    CrossrefPubMedGoogle Scholar
  • 47 Huisman MV, Büller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95 (03) 498-502
    CrossrefPubMedGoogle Scholar
  • 48 DeBiasi RL, Song X, Delaney M. et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, Metropolitan region. J Pediatr 2020; 223: 199-203.e1
    CrossrefPubMedGoogle Scholar
  • 49 Chao JY, Derespina KR, Herold BC. et al. Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City. J Pediatr 2020; 223: 14-19.e2
    CrossrefPubMedGoogle Scholar
  • 50 Del Borrello G, Giraudo I, Bondone C. et al. SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study. J Thromb Haemost 2021; 19 (02) 522-530
    CrossrefPubMedGoogle Scholar
  • 51 Goldenberg NA, Sochet A, Albisetti M. et al; Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost 2020; 18 (11) 3099-3105
    CrossrefPubMedGoogle Scholar
  • 52 Chowdhury JF, Moores LK, Connors JM. Anticoagulation in hospitalized patients with Covid-19. N Engl J Med 2020; 383 (17) 1675-1678
    CrossrefPubMedGoogle Scholar
  • 53 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18 (07) 1743-1746
    CrossrefPubMedGoogle Scholar
  • 54 Phend C. Trials halt full-dose clot prophylaxis for severe COVID-19 — Safety concerns cited in ACTIV-4, REMAP CAP, and ATTACC. Accessed April 27, 2021 at: https://www.medpagetoday.com/infectiousdisease/covid19/90351
    PubMedGoogle Scholar
  • 55 Siegal DM, Barnes GD, Langlois NJ. et al. A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. Blood Adv 2020; 4 (24) 6259-6273
    CrossrefPubMedGoogle Scholar